Research programme: diabetes therapy - Oxford BioMedica

Drug Profile

Research programme: diabetes therapy - Oxford BioMedica

Alternative Names: Diabetes therapy research programme - Oxford BioMedica

Latest Information Update: 13 Aug 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford BioMedica
  • Class Cell therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 13 Aug 2003 Discontinued - Preclinical for Type-1 diabetes mellitus (unspecified route)
  • 19 May 2003 No development reported - Preclinical for Type-1 diabetes mellitus (unspecified route)
  • 05 Oct 2001 Oxford BioMedica and Modex Therapeutics terminated their collaboration on diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top